Committee approves printing of RS 31966, a proposed moratorium on experimental gene-therapy immunizations

Senator Brandon Shippey introduced RS 31966, which would establish a temporary moratorium on experimental human gene therapy products when used as immunizations for infectious-disease indications. The sponsor described the proposal as a pause to allow time for review of safety and long-term effects before such products could be used as vaccines for infectious diseases.

Shippey said the proposal is named for Doug Cameron, an Idaho rancher he said experienced a severe adverse outcome after receiving a genetic immunization. Shippey framed the RS as a safety and transparency measure and asked the committee to send the request-to-print so the bill can be drafted and scheduled for a hearing.

Senator Melissa Wintrow asked several procedural and substantive questions, including how the moratorium would define covered products and whether individuals could consent to certain treatments. Shippey said those details — exemptions, consent, and scope — would be addressed in the full committee hearing and that experts would be invited to testify. He also noted the draft includes an exemption provision on its second page.

Senator Lenny moved to send RS 31966 to print; Senator Keiser seconded the motion. The committee approved the request-to-print by voice vote with no recorded opposition.

RS 31966 will be drafted into bill language and return to committee for a hearing where sponsors said they plan to address definitions, exemptions and expert testimony on safety and long-term effects.